, on behalf of the Dutch Health Council, reported on their recent advice on the preferable vitamin D status. They conclude that X30 nmol/l 25-hydroxyvitamin D (25(OH)D) is adequate for women aged p50 and men aged p70 years, while 450 nmol/l is adequate at a higher age. The 75-80 nmol/l 25(OH)D limit of adequacy (Heaney et al., 2003) is not advised, because 'Achieving such levels requires a vitamin D intake that has not been extensively studied and may exceed the tolerable upper intake level of 50 mg/day as defined by the European Food Safety Authority'. The risks are elevated calcium levels in blood and urine, and the formation of kidney stones. Interestingly, however, this 75-80 nmol/l cut-off value is increasingly suggested in papers on vitamin D in nutritional journals, which illustrates the growing gap between the opinions of prominent vitamin D experts and health authorities.
The discrepancy between the 75-80 nmol/l 25(OH)D adequacy level and the 50 mg vitamin D upper tolerable level should rather prompt the authors to question the upper tolerable level than the 75-80 nmol/l cut-off, as 50 mg vitamin D/day will cause 25(OH)D to increase by no more than about 35 nmol/l. The European Scientific Committee on Food has set the 'no observed adverse effect level' at 100 mg vitamin D/ day, while specialists (Hathcock et al., 2007) advocate a 'no observed adverse effect level' and an upper tolerable level of 250 mg/day (10 000 IU). The European Scientific Committee on Food set the 'no observed adverse effect level' of the status at 200 nmol/l 25(OH)D and also noted that no hypercalcemia and hypercalciuria occur at the upper reference value of 150 nmol/l. Subjects enjoying abundant sunshine have 100-200 nmol/l 25(OH)D levels without signs of toxicity. Finally, a systematic study indicated that vitamin D toxicity with convincing hypercalcemia occurs at 25(OH)D levels well above 200 nmol/l, most probably from around 375 nmol/l.
Contemporary health authorities advising on nutrients exaggerate vitamin D toxicity. This originates from the habit to correct 'no observed adverse effect levels' or 'lowest observed adverse effect levels' to upper tolerable levels using 'uncertainty factors'. Such factors are appropriate in many cases, but might be quite inappropriate for nutrients with relatively small intervals between the recommended dietary allowance and the lowest observed adverse effect level, such as vitamin D. Although these authorities keep referring to 'evidence-based medicine' in their vitamin D advice, they do not provide justification for introducing an uncertainty factor of 2 to account for inter-individual variation. Moreover, with an uncertainty factor of 2, the upper tolerable level of the status becomes 100 nmol/l 25(OH)D, which is well above the 75-80 nmol/l target.
It is high time to rethink the scientific basis of dietary reference intakes and to introduce genuine risk-benefit analyses using various scenarios. The mere reliance on randomized controlled trials is inadequate and constitutes a serious misinterpretation of evidence-based medicine (Sackett et al., 2000) . Present and future generations deserve a realistic weighing of pros and cons to arrive at an optimal vitamin D status according to all contemporary insights.
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